Loading...
XNAS
EDAP
Market cap89mUSD
Dec 05, Last price  
2.40USD
1D
0.21%
1Q
-4.76%
Jan 2017
-26.83%
Name

Edap Tms SA

Chart & Performance

D1W1MN
XNAS:EDAP chart
P/E
P/S
1.20
EPS
Div Yield, %
Shrs. gr., 5y
4.71%
Rev. gr., 5y
7.38%
Revenues
64m
+6.11%
20,794,51020,265,17622,362,10523,053,00024,885,00023,708,00022,292,00026,065,00024,079,00026,785,00032,253,00035,611,00035,746,00039,182,00044,911,00041,662,00044,066,00055,109,00060,423,00064,115,000
Net income
-19m
L-10.20%
0001,597,000-7,766,000-12,717,000-938,000-7,475,000-5,021,000-512,000-1,667,0003,842,000-681,000-338,0001,512,000-1,704,000700,000-2,933,000-21,178,000-19,018,000
CFO
-14m
L-7.45%
000-4,593,000-3,664,000-3,818,000-737,000-162,000-2,495,000-1,014,0001,338,0001,119,000-3,059,000175,0003,800,0001,977,0004,445,000-3,024,000-14,678,000-13,584,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
IPO date
Aug 01, 1997
Employees
264
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT